These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27385175)

  • 1. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.
    Fan Y; Sun B; Agarwal S; Zhang L
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S193-204. PubMed ID: 27385175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US FDA's Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape from Traditional to Novel Therapies.
    Gendy JM; Nomura N; Stuart JN; Blumenthal G
    Ther Innov Regul Sci; 2024 Mar; 58(2):380-386. PubMed ID: 38182940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade.
    Younis IR; Manchandani P; Hassan HE; Qosa H
    Clin Pharmacol Ther; 2022 Sep; 112(3):635-642. PubMed ID: 35780478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A descriptive analysis of postmarketing requirement studies and clinical trials.
    Choi L; Etchey B; Billings M; Lee C; Weil KM; Boxwell D; Edelberg H
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5725. PubMed ID: 37994284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
    Dauner DG; Dauner KN; Peterson ALH
    Res Social Adm Pharm; 2020 Jun; 16(6):844-847. PubMed ID: 31812502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.
    Moneer O; Brown BL; Avorn J; Darrow JJ; Mitra-Majumdar M; Joyce KW; Ross M; Pham C; Kesselheim AS
    Drug Saf; 2022 Apr; 45(4):305-318. PubMed ID: 35182362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors That Influence FDA Decisions for Postmarketing Requirements and Commitments During Review of Oncology Products.
    Hyogo A; Kaneko M; Narukawa M
    J Oncol Pract; 2018 Jan; 14(1):e34-e41. PubMed ID: 29136389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating the Impact of Immunogenicity Assessment Postapproval: A Targeted Analysis of Immunogenicity Postmarketing Requirements and Commitments.
    Guinn D; Madabushi R; Wang YM; Zineh I; Maxfield K
    Clin Pharmacol Ther; 2021 Mar; 109(3):697-704. PubMed ID: 32895941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation.
    Avachat C; Younis IR; Birnbaum AK
    Clin Pharmacol Ther; 2023 Dec; 114(6):1238-1242. PubMed ID: 37750407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's first active medical product surveillance eyes antidiabetic-MI link.
    Thompson CA
    Am J Health Syst Pharm; 2011 Apr; 68(7):550-1. PubMed ID: 21411791
    [No Abstract]   [Full Text] [Related]  

  • 14. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs.
    Zettler ME
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 18. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
    Nicholson S; Peterson J; Yektashenas B
    Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.